Share Twitter LinkedIn Facebook Email Immune checkpoint inhibitors are now becoming approved and commercially available for patients with previously treated advanced NSCLC. Dr. Eddie Garon, medical oncologist at UCLA, summarizes key data and explains their current role in treatment.
Immunotherapy Side Effects Under Scrutiny: New Data on Bone Density and T-Cell Insights AACR 3 Mins Read
Immunotherapy Revolution Unveiled: How TLS-Derived Antibodies Are Changing Cancer Treatment AACR Io 2025 AACR 4 Mins Read
AACR IO 2025: Revolutionary Insights into Desmoplastic Melanoma Treatment – Kari L Kendra, MD, PHD AACR 5 Mins Read